Delving into the Latest Updates on Sequoia Pharmaceuticals, Inc. with Synapse

Overview

We have designed and synthesized a series of HIV protease inhibitors (PIs) with enamino-oxindole substituents optimized to interact with the S2' subsite of the HIV protease binding pocket. Several of these inhibitors have sub-nanomolar K(i) and antiviral IC(50) in the low nM range against WT HIV and against a panel of multi-drug resistant (MDR) strains.

19 May 2006·Science (New York, N.Y.)Q1 · CROSS-FIELD

Translation Research and Drug Development

Q1 · CROSS-FIELD

Letter

Author: Erickson, John

Jocelyn Kaiser's recent article on “translational research” (“A cure for medicine's ailments?,” News Focus, 31 Mar., p. [1852][1]) sounded an encouraging note to basic and clinical researchers alike who yearn to test their pet ideas for new cures. According to Kaiser, translational research

100 Deals associated with Sequoia Pharmaceuticals, Inc.

Login to view more data

100 Translational Medicine associated with Sequoia Pharmaceuticals, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data